Medifast Reaches Cooperation Agreement with Activist Investor Steamboat Capital, Adds Two Directors
MED is trading near its 52-week low of $9.22 (9.2% above the low).
Summary
Medifast has entered into a cooperation agreement with activist investor Steamboat Capital, which holds a significant stake, leading to the appointment of two Steamboat designees to the Board and the departure of two existing directors.
Key Events · Executive and Board Changes · MED
-
Cooperation Agreement Signed
Medifast entered into a Cooperation Agreement with activist investor Steamboat Capital Partners on March 19, 2026.
-
Activist Board Representation
Two Steamboat Capital designees, Parsa Kiai and Jeffrey Rose, will be nominated for election to Medifast's Board of Directors at the 2026 Annual Meeting.
-
Director Departures
Existing directors Jeffrey Brown and Michael Hoer will not stand for re-election, making way for the new appointments.
-
Significant Activist Stake
Steamboat Capital beneficially owns approximately 5.98% of Medifast's outstanding shares.
Analysis · MED · Manufacturing
This agreement signals increased shareholder oversight and potential strategic shifts for Medifast, which recently reported a substantial revenue decline and net loss. The activist investor's representation on the board, coupled with a standstill agreement, suggests a collaborative effort to improve financial performance and unlock shareholder value. Investors will be watching for how these new board members influence the company's strategy, particularly in light of competitive pressures from GLP-1 weight loss medications.
At the time of this filing, MED was trading at $10.07 on NYSE in the Manufacturing sector, with a market capitalization of approximately $110.7M. The 52-week trading range was $9.22 to $15.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.